SCHEMBL15511646

SCHEMBL15511646

O=C(O)c1ccc2cnc(NC3CCOCC3)cc2c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.55
RPS6KA1 Q15418 4/20 0.55
HCAR3 P49019 3/20 0.55
CCNE1 P24864 5/20 0.53
CDK2 P24941 5/20 0.53
DYRK1A Q13627 4/20 0.48
GSK3B P49841 3/20 0.48
WNT1 P04628 2/20 0.46
ABL1 P00519 1/20 0.46
HPGDS O60760 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
CLK2 P49760 1/20 0.43
CLK3 P49761 1/20 0.43
MAPK3 P27361 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15511488 0.93 HCAR3 (0.52) MAPK1RPS6KA1HCAR3CCNE1CDK2
SCHEMBL15551934 0.82 HCAR3 (0.54) MAPK1RPS6KA1HCAR3DYRK1AGSK3B
SCHEMBL15551931 0.82 HCAR3 (0.54) MAPK1RPS6KA1HCAR3DYRK1AGSK3B
SCHEMBL15583701 0.82 HCAR3 (0.54) MAPK1RPS6KA1HCAR3DYRK1AGSK3B
SCHEMBL15511824 0.82 MAPK1 (0.43) MAPK1RPS6KA1HCAR3DYRK1AGSK3B
SCHEMBL15511812 0.79 CCNE1 (0.72) MAPK1RPS6KA1HCAR3CCNE1CDK2
SCHEMBL14676324 0.79 MAPK1 (0.56) MAPK1CCNE1CDK2
SCHEMBL15551641 0.77 HCAR3 (0.54) HCAR3ABL1HPGDS
SCHEMBL15551643 0.77 HCAR3 (0.54) HCAR3ABL1HPGDS
SCHEMBL17914073 0.76 MAPK1 (0.75) MAPK1RPS6KA1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2888247-B1 SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES ARRAY BIOPHARMA INC (US) 2020-03-25 EP disclosed
US-9388171-B2 Serine/threonine kinase inhibitors GENETECH, INC. (US) 2016-07-12 US disclosed
EP-2888247-A1 SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE!DISEASES Array Biopharma, Inc. (US) 2015-07-01 EP disclosed
WO-2014036015-A1 SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE|DISEASES ARRAY BIOPHARMA INC. (US) 2014-03-06 WO disclosed
US-20140066453-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2014-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066453-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K2, MAP3K20 MAPK1 28/4885RPS6KA1 98/4885HCAR3 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.